Toronto (ots/PRNewswire) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 (collectively, the "Aion Mushroom Preparations" or "Preparations") showed high efficacy in killing HER2+ breast ...
Vancouver, Bc (ots/PRNewswire) - Precision NanoSystems (PNI), a global leader in innovative solutions for genetic medicine development, today launched the GenVoy-ILM(TM) T Cell Kit for mRNA to enable lipid nanoparticle (LNP)-based ex vivo gene transfer. Scientists can now use mRNA-LNP to efficiently and reproducibly ...
Bagsværd, Denmark (ots/PRNewswire) - Data presented at ENDO 2021 demonstrate clinically relevant weight loss, without weight regain, in people treated with semaglutide 2.4 mg vs placebo in combination with lifestyle intervention. New results from the STEP phase 3a clinical trial programme demonstrated weight loss ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for US-, Canada- or UK-based media Merck, a leading science and technology company, today announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or ...
Almere, Netherlands (ots/PRNewswire) - There is a strict embargo on this press release and article until the time of its scheduled publication (March 5th, 2021 at 2pm ET). The link to the article, which will go live upon publication: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0246828 The influential open access journal PLOS ONE published an ...
Darmstadt, Germany (ots/PRNewswire) - MAGNIFY-MS retrospective analysis demonstrates patients develop protective antibody levels for at least six months following seasonal influenza and varicella zoster vaccines, irrespective of vaccine timing relative to MAVENCLAD dosing Initial findings from the CLOCK-MS vaccine ...
Lausanne, Switzerland and Seongnam-si Gyeonggi-do, Republic of Korea (ots) - Korean and Swiss based companies leverage their oncology expertise to initiate a research collaboration to formulate novel antibody-drug conjugate (ADC) candidates Genome & Company (314130, CEO: Jisoo Pae, Hansoo Park), a global leading ...
Schweizerischer Nationalfonds / Fonds national suisse
Bern (ots) - Bacteria can survive antibiotic treatment even without antibiotic resistance by slowing down their metabolism and going into a type of deep sleep. A research team funded by the Swiss National Science Foundation reveals the changes bacteria undergo to reach this "persister" state. Resistant bacteria evade the effects of antibiotics by becoming less susceptible, for example by breaking the drugs down. But some ...
Dublin (ots/PRNewswire) - - Newly created role of Chief Business Officer to drive commercialization strategy including partnering SOLUPORE®, Avectas' non-viral cell engineering technology - Daniel Castro brings 25 years of healthcare and pharmaceutical industry experience, with a focus on licensing and deal-making - Based in Boston, MA, at the heart of a major global biotech cluster Avectas, a cell engineering company ...
SIFI Press & Communication Office
Catania, Italy (ots/PRNewswire) - Given urgency to treat, SIFI has established a dedicated cross-functional team to accelerate the launch of polihexanide monotherapy in Europe and the United States. SIFI, a leading ophthalmic company, is pleased to announce the recent appointment of Jelle Kleijn, PhD, as Global Head ...
Darmstadt, Germany (ots/PRNewswire) - Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has validated for review, the application for tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial ...
Fresenius Kabi Deutschland GmbH
BAD HOMBURG (ots) - Evidence indicates that omega-3 (?-3) fatty acid containing parenteral nutrition (PN) improves clinical outcomes compared with standard PN in adult patients,1 underlining its role in today's hospitals and clinics. To support continuous health care professional (HCP) education on omega-3 fatty ...
Bagsværd, Denmark (ots/PRNewswire) - Results of a phase 3a trial showed that investigational drug semaglutide 2.4 mg once-weekly subcutaneous as an adjunct to intensive behavioural therapy (IBT) demonstrated significantly more body weight loss compared to placebo plus IBT.[i] The STEP 3 phase 3a trial investigated ...
Dublin (ots/PRNewswire) - - Avectas announces residency at Johnson & Johnson Innovation - JLABS @ Toronto, central to the Canadian bio-hub. - Jessica Schwaber, PhD appointed Scientific Director of Cell and Gene Therapy. Avectas, a cell engineering technology business, is pleased to announce it has been accepted to become a resident at Johnson & Johnson Innovation - JLABS @ Toronto. JLABS @ Toronto is a 40,000 square-foot ...
Lausanne (ots) - For its sixteenth edition, the JCA-Mauvernay Award was awarded to Doctor Hideaki Ogiwara and Doctor Keisuke Kataoka Debiopharm (www.debiopharm.com), a Swiss-based global, biopharmaceutical company, presented the JCA-Mauvernay Award on October 3rd to Dr. Hideaki Ogiwara from the Division of Cancer Therapeutics of the National Cancer Center Research ...
Lausanne, Switzerland (ots) - First patient dosed in the randomized, placebo-controlled Phase III study of xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) Debiopharm (www.debiopharm.com), a ...
Lausanne, Switzerland (ots) - Debiopharm, (www.debiopharm.com), a Swiss-based biopharmaceutical company today announced being one of the recipients of the 2020 Swiss Biotech Success Story Award for exceptional achievements in the biotech industry. Every year, the Swiss Biotech Association awards companies or ...
Lausanne, Switzerland (ots) - Debiopharm announces the presentation of the 3-year phase II follow-up data along with 2 posters for xevinapant (antagonist of IAP -Inhibitor of Apoptosis Proteins) and WEE1 inhibitor Debio 0123 Debiopharm, ...
Darmstadt, Germany (ots/PRNewswire) - · New analyses from Phase III JAVELIN Bladder 100 study of BAVENCIO®* assess efficacy across subgroups, patient-reported outcomes and exploratory biomarkers in advanced urothelial cancer · Overall efficacy data, and analyses of brain metastases and HRQoL for tepotinib? from ...
Darmstadt, Germany (ots/PRNewswire) - In MAGNIFY-MS, patients experienced a rapid onset of action from end of Month 1 that was significant in all study periods versus baseline Post-approval safety analysis showed no increased risk of viral respiratory infections and lower rates of malignancy than in the clinical ...
Brussels (ots/PRNewswire) - - Phase II data demonstrated clinically meaningful platelet count increases with meaningful decreases in IgG concentration - Rozanolixizumab's subcutaneous route of administration shows potential to deliver targeted individualized patient care for people living with Primary Immune ...
Lausanne (ots) - First patient dosed in the phase I small cell lung cancer (SCLC) trial with Debio 1124, a molecular-targeted radiotherapy Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, today announced the first patient dosed in the multicenter, single-arm, open-label Phase 1 study ...
Lausanne, Switzerland (ots) - Promising overall survival outcomes at 3-years for high-risk, locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) patients observed with Debio 1143 + CRT Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, today announced the release of ...
Norgine; AMAG Pharmaceuticals, Inc.
Waltham, Mass. and Amsterdam (ots/PRNewswire) - Agreement provides AMAG with $30 million upfront payment and eligibility to receive up to $260 million in development and commercial milestones in addition to sales royalties Collaboration further advances the development of ciraparantag AMAG Pharmaceuticals, Inc. ...
Basel, Switzerland (ots) - Versameb AG, a biopharmaceutical company developing innovative ribonucleic acid (RNA) therapeutics, announced today the closing of a CHF 6 million seed financing round. Versameb further strengthens its team by the appointment of Dr. Klaas P. Zuideveld as Chief Development Officer effective ...
Tokyo and Deventer, Netherlands (ots/PRNewswire) - Terumo Corporation (TSE: 4543) today announced it has completed the acquisition of Quirem Medical B.V., a Netherlands-based healthcare startup specializing in the development of next-generation microspheres for Selective Internal Radiation Therapy (SIRT), a treatment for liver tumors. Under the terms of the agreement, ...
Munich (ots/PRNewswire) - - Daiichi Sankyo presented five abstracts from the Global and European ETNA-VTE registry studies at ISTH 2020 Virtual Congress - Data are from 4,595 VTE patients (mean age 64) from 583 sites across Europe, Japan and other East and South-east Asian countries - Real-world study adds to the ...
Hattersheim, Germany (ots/PRNewswire) - European Medicines Agency Approves 21-Day Dosing Intervals for Adult Haemophilia B Patients Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) has approved the new Summary of Product Characteristics, which includes information about new, extended dosing options for IDELVION® ...
London (ots/PRNewswire) - - Piers Morgan appointed earlier in the year as Chief Financial Officer and Gary Gilmour as Director of Preclinical Research COMPASS Pathways, a mental health care company, announced today that it has made a number of new appointments to its leadership team. Trevor Mill joins the company as ...